These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24851137)

  • 1. Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.
    Krasowski MD; Ekins S
    J Cheminform; 2014; 6():22. PubMed ID: 24851137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.
    Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD
    Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-reactivity of commercial immunoassays for screening of new amphetamine designer drugs. A review.
    Nieddu M; Baralla E; Pasciu V; Rimoli MG; Boatto G
    J Pharm Biomed Anal; 2022 Sep; 218():114868. PubMed ID: 35688007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays.
    Martinez-Brokaw CD; Radke JB; Pierce JG; Ehlers A; Ekins S; Wood KE; Maakestad J; Rymer JA; Tamama K; Krasowski MD
    BMC Clin Pathol; 2019; 19():2. PubMed ID: 30820187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays.
    Swortwood MJ; Hearn WL; DeCaprio AP
    Drug Test Anal; 2014; 6(7-8):716-27. PubMed ID: 23677923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of designer drug cross-reactivity on five commercial immunoassay screening kits.
    Regester LE; Chmiel JD; Holler JM; Vorce SP; Levine B; Bosy TZ
    J Anal Toxicol; 2015 Mar; 39(2):144-51. PubMed ID: 25492523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.
    Krasowski MD; Pizon AF; Siam MG; Giannoutsos S; Iyer M; Ekins S
    BMC Emerg Med; 2009 Apr; 9():5. PubMed ID: 19400959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction.
    Krasowski MD; Drees D; Morris CS; Maakestad J; Blau JL; Ekins S
    BMC Clin Pathol; 2014; 14():33. PubMed ID: 25071417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of commercial multi-drug oral fluid devices to identify 39 new amphetamine-designer drugs.
    Nieddu M; Burrai L; Trignano C; Boatto G
    Leg Med (Tokyo); 2014 Mar; 16(2):106-9. PubMed ID: 24360925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing.
    Reschly-Krasowski JM; Krasowski MD
    Acad Pathol; 2018; 5():2374289518811797. PubMed ID: 30480089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology.
    Leclercq M; Soichot M; Delhotal-Landes B; Bourgogne E; Gourlain H; Mégarbane B; Labat L
    J Anal Toxicol; 2020 Mar; 44(2):200-205. PubMed ID: 31384953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays.
    Begeman A; Franssen EJF
    Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of urine samples taken from Ecstasy users at Rave parties: analysis by immunoassays, HPLC, and GC-MS.
    Zhao H; Brenneisen R; Scholer A; McNally AJ; ElSohly MA; Murphy TP; Salamone SJ
    J Anal Toxicol; 2001; 25(4):258-69. PubMed ID: 11386639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement.
    Nakanishi K; Miki A; Zaitsu K; Kamata H; Shima N; Kamata T; Katagi M; Tatsuno M; Tsuchihashi H; Suzuki K
    Forensic Sci Int; 2012 Apr; 217(1-3):174-81. PubMed ID: 22154438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of new classes of recreational drugs in sewage: synthetic cannabinoids and amphetamine-like substances.
    Reid MJ; Derry L; Thomas KV
    Drug Test Anal; 2014; 6(1-2):72-9. PubMed ID: 23460377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays.
    Krasowski MD; Siam MG; Iyer M; Pizon AF; Giannoutsos S; Ekins S
    Clin Chem; 2009 Jun; 55(6):1203-13. PubMed ID: 19342505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays.
    Krasowski MD; Siam MG; Iyer M; Ekins S
    Ther Drug Monit; 2009 Jun; 31(3):337-44. PubMed ID: 19333148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELISA Detection of 30 New Amphetamine Designer Drugs in Whole Blood, Urine and Oral Fluid using Neogen® "Amphetamine" and "Methamphetamine/MDMA" Kits.
    Nieddu M; Burrai L; Baralla E; Pasciu V; Varoni MV; Briguglio I; Demontis MP; Boatto G
    J Anal Toxicol; 2016 Sep; 40(7):492-7. PubMed ID: 27405364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry.
    Shanks KG; Dahn T; Behonick G; Terrell A
    J Anal Toxicol; 2012 Jul; 36(6):360-71. PubMed ID: 22586208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic drugs of abuse.
    Tamama K
    Adv Clin Chem; 2021; 103():191-214. PubMed ID: 34229850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.